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Objective: To evaluate the stature growth rate (GR) and the weight gain of 
prepubertal asthmatic children.
Method: A retrospective cohort study evaluating medical records of 85 children 
diagnosed with asthma, aged less than 9 years, of both sexes, with at least one 
year of follow-up in the allergy outpatient clinic. The data on the disease, weights 
and heights were collected through a standardized questionnaire on two occasions, 
with an interval of one year. The curves proposed by Tanner were applied for the 
analysis of the GR, and the Z-score of the GR (ZGR) was calculated.
Results: Excess weight (risk for overweight, overweight and obesity) was observed 
in 31.8% (27/85) of the patients, but there was no association with the severity of 
asthma. Low GR (ZGR < -2) was found in 13.9% (11/79) of patients, most frequently 
among children with moderate/severe persistent asthma compared to persistent 
mild and intermittent forms (7/11 – 63.6% vs. 21/68 – 30.2%, respectively, p=0.047). 
Use of steroids (dose, type and time of use) was not associated with GR.
Conclusion: GR was most affected in children with moderate/severe asthma.
Keywords: asthma, children, nutritional status, corticosteroids, weight-height.
introduction
Currently, it is estimated that about 300 million people 
have asthma worldwide. Adequate treatment allows for 
satisfactory control of symptoms and improvement of 
the quality of life of affected individuals.1 
Inhaled corticosteroids (IC) are the main medications 
currently used in the maintenance treatment of patients 
with asthma, because they reduce the frequency and sever-
ity of attacks. Its use is associated with fewer hospitaliza-
tions and care in emergency services, better quality of life 
and improved lung function.2  The goal of treatment is 
control of the disease and remission of exacerbations with 
the lowest possible doses.1
Systemic adverse events are described with varying 
intensity and dependent on the drug, dose and time of 
use, including: loss of bone mass, inhibition of the hypo-
thalamic pituitary adrenal axis and growth deficit (with 
no change in growth cartilage).c However, there is debate 
as to the damage of growth in asthmatic children being 
more intense when the disease is not controlled, and that 
even with the use of IC the benefits related to disease 
control overlap with possible adverse events.1 
In Brazil, in the pediatric population in general, the 
prevalence of stature impairment has been significantly 
reduced in the last decades. Nevertheless, it is still great-
er than observed in developed countries.4 It is therefore 
important to evaluate the growth profile of asthmatic 
children in our country, using the currently recommend-
ed treatment protocols. 
The goal of our study was to evaluate the stature 
growth rate (GR) and the weight gain of prepubertal asth-
matic children.
Method
In a retrospective cohort study, we evaluated the charts 
of children diagnosed with asthma according to the 
Global Initiative for Asthma (GINA).5 The patients were 
sensitized to aeroallergens, aged over 2 and under 9 years, 
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of both sexes, enrolled and regularly monitored for at 
least one year in the outpatient clinic of the Division of 
Allergy, Clinical Immunology and Rheumatology of the 
Pediatrics Department of Escola Paulista de Medicina da 
Universidade Federal de São Paulo (EPM-Unifesp). 
The study was approved by the Research Ethics Com-
mittee of EPM-Unifesp (No. 65814/2012). Patients with 
non-allergic asthma (lack of sensitization to aeroallergens) 
and other chronic non-allergic diseases (endocrinopathies, 
autoimmune diseases, immunodeficiencies, genetic syn-
dromes) were excluded.
Data were collected from electronic medical records 
available at EPM-Unifesp and all consultations whose 
International Code of Diseases (ICD) was related to asth-
ma (J45) were assessed. 
After evaluation of the medical records and application 
of the inclusion and exclusion criteria, 85 patients were 
included. Patient data were collected from these 85 medi-
cal charts through a standardized questionnaire containing: 
identification data; personal, feeding (total breastfeeding 
duration) and morbid (hospitalizations, previous and cur-
rent diseases) history; results of hypersensitivity tests; pres-
ence of domestic animals and smokers at home; other 
associated allergic diseases; classification and control of 
asthma (GINA); medication used (IC and oral) and respec-
tive dosages; maximum expiratory flow rate; weight and 
height with a maximum interval of 6 months (± 2 months). 
Considering that different types of IC were used, the 
doses received were converted to beclomethasone as a refer-
ence.5 In addition, the IC propellant was taken into account: 
400 mcg of inhaled budesonide powder corresponded to 
250 mcg of beclomethasone HFA spray; 250 mcg of fluti-
casone or mometasone HFA spray amounted to 500 mcg 
of beclomethasone HFA spray. Prednisone was the oral 
corticosteroid (OC) most commonly used by patients. Based 
on dosage calculation of beclomethasone/day, doses equal 
to or greater than 400 mcg/day, between 200 and 400 mcg/
day, and below 200 mcg/day were considered, respectively, 
as high, medium and low exposure.5
Weight and height data were used to calculate a Z-score 
of body mass index for age (Z-BMI) and height for age 
(H/A), using WHO Anthro Plus® software, which were 
compared to World Health Organization (WHO) refer-
ence values (2006 and 2007).6 The curves proposed by 
Tanner were applied for the analysis of the GR.7
SPSS 19.0 package was used for statistical analysis, and 
continuous variables were tested for their normality by means 
of the Kolmogorov-Smirnov test, being compared by the 
Mann-Whitney test (non-parametric data) and Student’s 
t-test (parametric) for independent variables. T-Paired test 
and Freedman’s test were applied to compare the nutrition-
al status at different times, for the parametric and non-para-
metric data, respectively. The level of significance was 5%. 
results
In the studied sample, males predominated (60/85 [70.6%]) 
and the median age was 5.5 years (2.1-8.4) (Table 1). The most 
prevalent nutritional disorders were risk for overweight 
15/85 (17.7%), overweight 5/85 (5.9%), and obesity 7/85 
(8.2%), while three children had a short stature 3/85 (3.5%).
TABLE 1 Characteristics of the population.
Variable Values
General characteristics
Gender (n=85) Male:Female 57:28a
Age at first evaluation (n=85) Years 5.5 (2.1-8.4)b
Age at second evaluation (n=85) Years 5.9 (2.6-8.7)b
Age at third evaluation (n=85) Years 6.5 (3.2-9.7)b
Pets (n=85) Yes 27 (31.8%)c
Smokers (n=85) Yes 37 (43.5%)c
Total breastfeeding  
duration (n=72)
< 6 months 62 (68.9%)c
Anthropometry
Nutritional status (n=85) Low stature and 
malnutrition
1 (1.2%)c
Low stature and 
normal weight
2 (2.4%)c
Malnutrition 1 (1.2%)c
Normal weight 54 (63.5%)c
Risk for overweight 15 (17.7%)c
Overweight 5 (5.9%)c
Obesity 7 (8.2%)c
Growth rate (n=85) Z score HA / year -0.3 (-6.2;5.2)b
Weight gain rate (n=85) Z score BMI / year 0.03 (-3.5;1.4)b
Asthma characteristics
Asthma classification (n=85) Intermittent 20 (23.5%)c
Persistent mild 32 (37.6%)c
Persistent 
moderate
31 (36.5%)c
Associated atopic  
diseases (n=85)
Rhinitis 82 (96.5%)c
Dermatitis 29 (34.1%)c
Attacks in the period between 
medical appointments (n=85)
Yes
Median (min-max)
37 (43.5%)c
1.0 (0.0-3.0)b
School absences due to asthma 
attacks (n=85)
Yes
Median in days 
(min-max)
41 (45.5%)c
1.5 (0.0-12.0)b
aAbsolute value.
bMedian (minimum-maximum).
cNumber and percentage.
HA: height for age; BMI: body mass index.
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Asthma was classified as intermittent in 20/85 (23.5%), 
persistent mild in 32/85 (37.6%) and persistent moderate/
severe in 31/85 (36.5%) of the evaluated patients. Allergic 
rhinitis and atopic dermatitis, concomitant to asthma, 
were described in 82/85 (96.5%) and 29/85 (36.4%) of the 
children, respectively.  
Asthma severity was not associated with the presence 
of other atopic diseases, overweight or obesity, gender, 
duration of breastfeeding, presence of pets or smokers at 
home (data not shown).
Low GR was observed in 11/79 (13.9%) of the children 
and, of all variables (Table 2), this was associated only 
with persistent moderate/severe asthma compared with 
persistent mild and intermittent forms (7/11 – 63.6% vs. 
21/68 – 30.2%; p=0.047) (Chart 1).
Use of IC and OC was observed in 60/79 (75.9%) and 
41/79 (51.8%) of the studied children, respectively. The 
frequency of OC use was low, on average once a year. Nei-
ther the use nor the dose of IC (Table 3) or OC was as-
sociated with worse GR in the children studied. 
discussion
The present study showed an association between low GR 
and asthma severity, regardless of IC treatment. Budesonide 
inhalation was the most commonly used IC, being avail-
able in the public health system and in the high-cost 
asthma medication program. 
Similar to the results observed here, a longitudinal 
study involving 315 children and adolescents with asthma 
and 82 controls, aged 7 to 14 years, showed height impair-
ment in patients with more severe disease and over 10 
years of age, especially in the group aged 14 years.8 Solé 
et al., in turn, in a study performed in the city of São 
Paulo, compared 397 patients with allergic diseases (asth-
ma, rhinitis, urticaria and atopic dermatitis), aged between 
8 months and 14 years, with 1,723 normal individuals, 
matched for age but of a higher socioeconomic profile, 
and they did not find any association between growth 
deficit and asthma severity.9  
Several situations could determine impaired growth 
when associated with asthma per se: early onset, disease du-
ration and severity, chest deformity, hypoxemia, changes in 
pulmonary function and increased metabolic demands 
due to increased ventilatory effort,10 in addition to low 
socioeconomic conditions,11 sedentary behavior12 and sleep 
disorders.1c Changes in growth hormone secretion, previ-
ously described, have not been proven in recent studies.14,15 
Pubertal delay and reversible deceleration of stature growth 
in the prepubertal period have also been described.16
There is no consensus in the literature about growth 
retardation associated with the use of IC. It should be 
noted that there are few clinical trials evaluating GR dur-
ing IC use and that it is difficult to compare these studies 
in view of the different treatments employed.17 
A recent systematic review and meta-analysis assessed 
the impact of different types and doses of IC (beclometh-
asone, budesonide, ciclesonide, fluticasone and mometa-
sone; alone or combined with long-acting beta-agonists) 
TABLE 2 Comparison of the variables studied in children regarding growth rate (GR).
Variable ZGR ≤ -2.0
(n=11)
ZGR > -2.0
(n=68)
p-value*
Sex Male 7 (63.4%) 45 (66.2%) 0.560
Age < 5 years 3 (27.2%) 32 (47.0%) 0.329
Attacks Yes 3 (27.2%) 36 (52.9%) 0.193
Nutritional status Normal weight vs. excess weight 0 (0.0%) 7 (10.0%) 0.585
Pets Yes 4 (36.4%) 21 (31.0%) 0.735
Smokers at home Yes 4 (36.4%) 31 (45.6%) 0.746
Breastfeeding < 6 months vs. > 6 months 4 (36.4%) 23 (33.8%) 0.560
Presence of rhinitis Yes 11 (100%) 65 (65.0%) 0.634
Presence of dermatitis Yes 4 (36.4%) 24 (35.3%) 0.597
Type of asthma Pers.mod vs. Interm + Pers.mild 7 (63.4%) 21 (31.0%) 0.047
Inhaled CS Yes 9 (81.8%) 51 (75.0%) 0.472
Intranasal CS Yes 11 (100%) 64 (94.1%) 0.542
Prednisolone Yes 4 (36.4%) 37 (54.4%) 0.338
Inhaled CS > 400 mg/day 6 (54.5%) 25 (36.7%) 0.474
*Level of significance of the Chi-square test or Fisher’s exact test.
Pers.mod vs. Interm + Pers.mild: persistent moderate vs. intermittent and persistent mild asthma; ZGR: Z score for growth rate; CS: corticosteroid.
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TABLE 3 Inhaled corticosteroid (IC) in patients with asthma, stratified according to growth rate (GR).
Z score for GR Total IC dose (mg/year) Duration of IC use (days) IC dose (mg/day) Duration of IC use (days)
≤ -2.0 Median 157,500.0 360.0 458.3 12.0
Minimum 22,500.0 90.0 195.6 3.0
Maximum 315,000.0 360.0 875.0 12.0
N 9 9 9 9
> -2.0 Median 123,750.0 345.0 400.0 11.5
Minimum 11,250.0 45.0 109.1 1.5
Maximum 510,000.0 360.0 1,625.0 12.0
N 51 51 51 51
Total Median 131,250.0 352.5 407.3 11.7
Minimum 11,250.0 45.0 109.1 1.5
Maximum 510,000.0 360.0 1,625.0 12.0
N 60 60 60 60
p-value 0.413 0.236 0.647 0.236
*Mann-Whitney test’s significance level.
CHART 1 Comparison of growth rate Z score according to asthma severity.
1: persistent moderate; 2: persistent mild asthma; 3: intermittent asthma.
ANOVA test (p=0.023).
Tukey’s range test: 1 vs. 3 (-1.31; p=0.038).
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on GR of asthmatic children revealing a modest but 
significant negative effect of moderate doses (100 to 
200 mcg/day of beclomethasone HFA) compared with 
low doses (50 to 100 mcg/day of beclomethasone HFA). 
There was no difference among ciclesonide, fluticasone 
and mometasone. The authors pointed out that in 86% 
of eligible clinical trials, there were no data on GR, or the 
information was incomplete. In addition, they emphasize 
the importance of including GR monitoring in future 
studies and reinforce the recommendation of lower IC 
doses in children following disease control and during 
their maintenance treatment.2 
The absence of an association between GR impair-
ment and IC in our study can be explained by the short 
interval between the two evaluations. Similar results 
were previously described by Singh et al. in preschoolers.18 
A review points to different results depending on the 
duration of exposure to treatment and the anthropo-
metric assessments performed.19 Other hypotheses to 
explain such findings may be low adherence to the treat-
ment prescribed, reduced numbers of patients with severe 
forms of asthma and individual variability due to ge-
netic characteristics. A study involving children with 
persistent asthma aged between 5 and 14 years showed 
low adhesion rates to beclomethasone propionate (mea-
sured by electronic monitor), corresponding to 31.2% 
after 12 months of treatment.20 
A recent meta-analysis showed a small, but significant, 
difference (-0.2 cm/year) in GR over 12 months in the group 
treated with a high IC dose schedule. Studies with a dura-
tion of more than one year and good methodological qual-
ity are scarce. We emphasize the importance and necessity 
of future studies with longer observation intervals.21 
Another concern is the persistence of reduction in the 
adult’s final height due to the use of IC as a child. A study 
that included 173,034 Swedish military recruits aged 18 
years (8,531 asthmatics) showed a discrete but significant 
difference in height between asthmatics and normal con-
trols, with a negative correlation between height and 
asthma severity.22
Adequate monitoring of anthropometric parameters 
and the identification of groups at risk for poor growth, 
especially in cases of severe asthma, should be treatment 
goals, favoring a better quality of life for the patients.  
Although in these studies the comparison between 
the different drugs is based on dose equivalence compared 
to beclomethasone, we cannot disregard the bioavail-
ability of these different drugs. Among ICs, beclometha-
sone is more bioavailable, i.e., there is a large amount of 
circulating drug after the first passage through the liver,2c 
unlike fluticasone, mometasone and ciclesonide. When 
these drugs are used in high doses, the adverse events 
occur in a linear way, as with beclomethasone. 
Although indicated as safe, patients on long-term IC 
treatment, regardless of dose and drug, should be moni-
tored for early diagnosis of possible adverse effects.
There are few studies evaluating weight gain in asth-
matic children and IC. What is known is that being over-
weight is associated with more severe asthma and more 
attacks. There seem to be several factors involved in this 
process. The most important are insulin resistance and the 
inflammatory state related to the increase of adipose tis-
sue.24 The association between obesity and asthma would 
potentiate the inflammatory state via TH1 and TH2 path-
ways. IC use is not related to greater weight gain in asth-
matic children.25 
conclusion
There is a greater impairment of the GR in asthmatic 
children with more severe forms (moderate/severe asth-
ma). The presence of associated rhinitis in 98.9% of the 
sample seems to suggest an important connection be-
tween the two allergic diseases (asthma and rhinitis). 
There was no association of GR with nutritional status, 
smoking, other allergic diseases, presence of pets at home, 
breastfeeding or use of steroids. The type, dose or time 
of use of corticosteroids did not negatively influence the 
GR of the asthmatic children analyzed in the study’s 
follow-up period.
The importance of outpatient follow-up for children 
with asthma should be emphasized, as it can positively 
influence the quality of life of these patients, since the 
control performed with inhalers seems to lead to a decrease 
in asthma attacks, preventing excessive and harmful ex-
posure to oral steroids (systemic). 
In addition, nutritional monitoring of asthmatic 
children is also a relevant factor for their quality of life. 
Since asthma, short stature and excess weight are chron-
ic diseases, it is believed that the association of these con-
ditions increases the risk of chronic non-communicable 
diseases in the future. Therefore, it would be interesting 
to develop strategies with combined protocols for inves-
tigation and treatment, aiming to improve these condi-
tions early and to reduce long-term repercussions. New 
perspectives to deepen the study of nutritional disorders 
(excesses and deficiencies) in asthmatic children would 
thus be explored. 
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resuMo
Velocidade de crescimento e ganho de peso em crianças 
pré-púberes asmáticas
Objetivo: Avaliar a velocidade de crescimento estatural 
e o ganho de peso de crianças asmáticas pré-púberes. 
Método: Estudo de coorte retrospectiva que avaliou 85 
prontuários de crianças com diagnóstico de asma, menores 
de 9 anos, de ambos os sexos, com no mínimo um ano de 
acompanhamento no ambulatório de alergia. Os dados 
relativos à doença, aos pesos e às alturas foram coletados 
por meio de questionário padronizado em dois momentos 
com intervalo de um ano. Para análise da velocidade de 
crescimento (VC), foram empregadas as curvas propostas 
por Tanner e realizado o cálculo do escore Z da VC (ZVC).
Resultados: O excesso de peso (risco para sobrepeso, 
sobrepeso e obesidade) foi observado em 31,8% (27/85) 
dos pacientes, mas sem associação com a gravidade da 
asma. Velocidade de crescimento baixa (ZVC < -2) foi 
encontrada em 13,9% (11/79) dos pacientes, com maior 
frequência entre as crianças com asma persistente mode-
rada/grave em relação às formas persistente leve e inter-
mitente (7/11 – 63,6% vs. 21/68 – 30,2%, respectivamente; 
p=0,047). O uso de corticosteroides (dose, tipo e tempo 
de uso) não mostrou associação com a VC.
Conclusão: Foi constatado um maior comprometimen-
to da VC em crianças com asma moderada/grave.
Palavras-chave: asma, crianças, estado nutricional, cor-
ticosteroides, peso-estatura.
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